Prevalencia de hiperandrogenismo y síndrome de ovario poliquístico en transexuales de mujer a hombre

Baba, 2007, Association between polycystic ovary syndrome and female-to-male transsexuality, Human Reproduction, 22, 1011, 10.1093/humrep/del474 Mueller, 2008, Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals, J Clin Endocrinol Metab, 93, 1408, 10.1210/jc.2007-2808 Vujovic, 2009, Transsexualism in Serbia: A twenty-year follow-up study, J Sex Med, 6, 1018, 10.1111/j.1743-6109.2008.00799.x Becerra-Fernández, 2009, Valoración del tratamiento hormonal cruzado en transexuales: Experiencia de una unidad de trastornos de identidad de género, Rev Int Androl, 7, 150 Bosinski, 1997, Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals, Arch Sex Behav, 26, 143, 10.1023/A:1024506427497 Balen, 1993, Polycystic ovaries are a common finding in untreated female to male transsexuals, Clin Endocrinol (Oxf), 38, 325, 10.1111/j.1365-2265.1993.tb01013.x Asunción, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434 Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study, J Clin Endocrinol Metab, 83, 3078 Ehrmann, 1999, Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome, Diabetes Care, 22, 141, 10.2337/diacare.22.1.141 Legro, 1999, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women, J Clin Endocrinol Metab, 84, 165 Sharma, 2006, Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers, Best Pract Res Clin Endocrinol Metab, 20, 245, 10.1016/j.beem.2006.02.003 Talbott, 2000, Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler Thromb Vasc Biol, 20, 2414, 10.1161/01.ATV.20.11.2414 Gooren, 2008, Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience, J Clin Endocrinol Metab, 93, 19, 10.1210/jc.2007-1809 Vermeulen, 1999, A critical evaluation of simple methods for the estimation of free testosterone in serum, J Clin Endocrinol Metab, 84, 3666, 10.1210/jcem.84.10.6079 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 9 Azziz, 2006, Androgen excess society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline, J Clin Endocrinol Metab, 91, 4237, 10.1210/jc.2006-0178 2002, Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Alberti, 2005, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome. A new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Matthews, 1985, Homeostatic model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883 Ascaso, 2001, Cuantificación de insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética, Med Clin (Barc), 117, 530, 10.1016/S0025-7753(01)72168-9 Vassiliadi, 2009, Increased 5α reductase activity and adrenocortical drive in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 94, 3558, 10.1210/jc.2009-0837 Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 Escobar-Morreale, 2005, The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome, Endocrine Reviews, 26, 251, 10.1210/er.2004-0004 Sir-Peterman, 1998, Naltrexone effects on insulin sensitivity and insulin secretion in hyperandrogenic women, Exp Clin Endocrinol Diabetes, 106, 389, 10.1055/s-0029-1212004 Mukherjee, 2010, Molecular & genetic factors contributing to insulin resistence in polycystic ovary syndrome, Indian J Med Res, 131, 743 Cupisti, 2010, The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome, Fertil Steril, 94, 2647, 10.1016/j.fertnstert.2010.03.048 Atmaca, 2006, Investigation of adrenal function in patients with idiopathic hyperandrogenemia, Eur J Endocrinol, 155, 307, 10.1530/eje.1.02212 Bruckert, 2007, HDL-c is a powerful lipid predictor of cardiovascular diseases, Int J Clin Pract, 61, 1905, 10.1111/j.1742-1241.2007.01509.x